RPL19 and cancer: RARA has a key role in the β-catenin function, and retinoid-based targets represent an important line of strategies for treating cancer [9]; while RPL19, a component of the 60S ribosomal proteins, is involved in the nucleolar structure with an impact on the regulation of p53 concentration [8].